Soberlink is the creator of an FDA cleared, remote breathalyzer used to detect alcohol usage in the United States.
The partnership will launch with a pilot program beginning in April of this year wherein certain patients whose risk for relapse is continuously measured by MAP’s patient engagement technology will be issued a Soberlink breathalyzer that links to the patient’s MAP profile.
The device, which utilizes facial recognition technology, will send real-time data to MAP’s care platform when a patient performs a test with negative results, misses scheduled tests, or tests positive for alcohol use.
With this information, MAP’s technology will inform the appropriate members of collaborative care teams if a patient is at an elevated risk for relapse or has returned to alcohol use.
Ultimately, this data is leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other means of mitigating recidivism and costly treatment episodes.
Of the patients served by MAP’s technology platform, 54.6 percent of all first post-acute treatment relapses involve alcohol, regardless of the patient’s drug of choice.
“The number one factor in improving outcomes is early intervention. Soberlink’s breathalyzer enables our eco-system of patients, providers, and health insurance companies to have a real-time understanding of who is at risk. The net result is saved lives and saved dollars,” says Jacob Levenson, CEO of MAP Health Management, LLC.
Assessing risk and informing care via remote, real-time breathalyzer results across large and diverse populations such as those managed by MAP’s technology is new to the addiction treatment space.
“We are excited to partner with MAP and deliver our breathalyzer technology to their ecosystem. Our FDA cleared device has shown in numerous studies to be a significant factor in improving outcomes. We are very excited to see the actionable data from our devices be utilized by MAP to improve outcomes,” says Brad Keays, CEO of Soberlink Healthcare, LLC.
MAP also recently announced a partnership with Intent Solutions, the makers of TAD, a biometric medication adherence device.
“We will be announcing more powerful partnerships soon that will significantly change how people with Substance Use Disorder are delivered care across the entire treatment continuum,” says Jacob Levenson.